Want to see SE:SEDANA full AI Analyst Report?
Sedana Medical AB (SEDANA) AI Stock Analysis
Sedana Medical AB
(Nasdaq OMX AB:SEDANA)
The score is mainly held back by continued losses and negative cash flow despite a strong balance sheet and sharp TTM revenue growth. Technical indicators are mildly weak (negative MACD and below the 50-day average), and valuation is constrained by a negative P/E with no dividend data.
Sedana Medical AB (SEDANA) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 926.81M
- Dividend Yield
- ―
- Average Volume (3M)
- 157.22K
- Price to Earnings (P/E)
- -26.9
- Beta (1Y)
- 0.90
- Revenue Growth
- 0.42%
- EPS Growth
- 15.03%
- Country
- Sweden
- Employees
- 117
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Sedana Medical AB Business Overview & Revenue Model
Company Description
Sedana Medical AB (publ) is a medical technology firm that engineers, promotes, and distributes healthcare devices both within Sweden and across global markets. Its product portfolio includes the Sedaconda ACD-L and Sedaconda ACD, single-use medical...
How the Company Makes Money
Sedana Medical makes money primarily by selling products used for inhaled ICU sedation. Key revenue streams include: (1) sales of its proprietary disposable administration device (Sedaconda ACD/ACD-S), which is used in the ventilator circuit to deliv...
Sedana Medical AB Financial Statement Overview
Summary
Strong TTM revenue growth (~152%) and very healthy gross margins (~71–72%) are positives, and the balance sheet is conservatively financed with extremely low leverage (TTM debt-to-equity ~0.007). However, the company remains loss-making (TTM net margin ~-17%, negative ROE) and is still consuming cash (negative operating cash flow and free cash flow), which materially limits the score.
Income Statement
44NeutralBalance Sheet
78PositiveCash Flow
32Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 198.44M | 200.23M | 178.75M | 153.87M | 122.86M | 159.15M |
| Gross Profit | 142.03M | 142.71M | 126.14M | 108.98M | 86.07M | 106.71M |
| EBITDA | -5.39M | -10.12M | -4.03M | -51.67M | -48.78M | -43.51M |
| Net Income | -34.54M | -59.24M | -10.67M | -59.61M | -73.51M | -57.97M |
Balance Sheet | ||||||
| Total Assets | 929.69M | 954.46M | 1.02B | 1.01B | 1.08B | 1.17B |
| Cash, Cash Equivalents and Short-Term Investments | 39.72M | 90.98M | 193.96M | 381.80M | 607.74M | 836.18M |
| Total Debt | 6.27M | 4.70M | 5.92M | 4.31M | 8.74M | 8.87M |
| Total Liabilities | 52.29M | 53.68M | 61.17M | 44.06M | 52.43M | 66.12M |
| Stockholders Equity | 877.40M | 900.78M | 958.26M | 970.00M | 1.03B | 1.10B |
Cash Flow | ||||||
| Free Cash Flow | -60.52M | -75.19M | -186.77M | -206.95M | -253.22M | -151.48M |
| Operating Cash Flow | -13.20M | -12.78M | -11.77M | -38.06M | -115.43M | -41.22M |
| Investing Cash Flow | -56.58M | -63.03M | -44.67M | -321.96M | -137.78M | -110.25M |
| Financing Cash Flow | -4.64M | -4.04M | -3.57M | -4.86M | -1.51M | 605.07M |
Sedana Medical AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEDANA, the sentiment is Negative. The current price of 9.33 is below the 20-day moving average (MA) of 9.60, below the 50-day MA of 10.28, and below the 200-day MA of 9.65, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 44.69 is Neutral, neither overbought nor oversold. The STOCH value of 19.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SEDANA.
Sedana Medical AB Peers Comparison
Overall Rating
SE:GETI.B67Neutral
SE:XVIVO64Neutral
SE:SEZI57Neutral
SE:BACTI.B53Neutral
SE:BRAIN53Neutral- SE:SEDANA51Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:GETI.B | 67Neutral | SEK 75.64B | 26.73 | 9.13% | 1.71% | -3.90% | 37.73% |
| SE:XVIVO | 64Neutral | SEK 6.46B | 50.12 | 5.89% | ― | 17.83% | 330.94% |
| SE:SEZI | 57Neutral | SEK 532.17M | -5.46 | -35.44% | ― | 18.56% | 28.11% |
| SE:BACTI.B | 53Neutral | SEK 560.70M | 88.89 | 1.93% | ― | -0.51% | ― |
| SE:BRAIN | 53Neutral | SEK 410.67M | -8.95 | -22.23% | ― | 6.49% | 25.03% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:SEDANA | 51Neutral | SEK 926.81M | -26.86 | -3.88% | ― | 0.42% | 15.03% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:SEDANA | Sedana Medical AB | 9.33 | -0.83 | -8.17% | |
| SE:GETI.B | Getinge AB (UK) | 277.70 | 60.83 | 28.05% | |
| SE:SEZI | Senzime AB | 3.38 | -2.45 | -41.94% | |
| SE:XVIVO | Xvivo Perfusion AB | 205.00 | 22.50 | 12.33% | |
| SE:BACTI.B | Bactiguard Holding AB | 16.00 | -1.00 | -5.88% | |
| SE:BRAIN | BrainCool AB | 1.04 | 0.45 | 76.27% |
Sedana Medical AB Corporate Events
Sedana Medical Returns to Sales Growth but Continues to Invest Heavily in Expansion
Sedana Medical reported third-quarter 2026 net sales of SEK 44.2 million, up 7 percent year-on-year, with gross margin slipping to 70 percent as contract manufacturing accounted for a larger share of revenue and prior-year margins benefited from a on...
Sedana Medical Sets Date for Q3 2026 Interim Report and Investor Presentation
Sedana Medical AB will publish its interim report for the third quarter of 2026 on October 22 at around 07:00 CET and follow up with an English‑language presentation at 13:30 CET the same day. Chief executive Johannes Doll, together with the co...
Sedana Medical Sets 2027 AGM Nomination Committee Representing Major Shareholders
Sedana Medical AB has appointed its Nomination Committee for the 2027 Annual General Meeting, in line with its governance principles that give the three largest shareholders, together with the Chairman of the Board, responsibility for preparing key A...
Sedana Medical Secures FDA PDUFA Date for Inhaled ICU Sedation Therapy
Sedana Medical AB has received a U.S. Food and Drug Administration Prescription Drug User Fee Act target action date of April 16, 2027 for its New Drug Application covering isoflurane delivered via the Sedana Medical ACD Delivery System for sedation...
Sedana Medical Wins FDA Review of Inhaled Sedation Drug for ICU Use
Sedana Medical AB said the U.S. Food and Drug Administration has accepted for review its New Drug Application for isoflurane delivered via the Sedana Medical ACD Delivery System to sedate mechanically ventilated adult ICU patients. The filing, suppor...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026